The treatment performs well when compared to its closest rival, Mounjaro, since it offers impressive weight loss potential at a lower price point
So what options exist for this group of people
In the 72-week non-diabetic obesity trial, adults lost -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg. Real-world outcomes vary because dose reached, adherence, and baseline state vary
The typical journey looks like this: Weeks 1-4: The adjustment phase (most challenging) Weeks 4-8: Significant improvement Month 3+: Most people feel comfortable and confident But dont suffer in silence
This is concerning because PWS is associated with a high rate of gastrointestinal issues, including chronic constipation, intestinal blockage, and delayed gastric emptying, along with an increased pain threshold